miconazole vaginal (Monistat-1 Combination Pack, Monistat-3 Combination Pack, Monistat-7 Combination Pack, Monistat-7 Vaginal Cream, Monistat-7 Vaginal Suppositories, Vagistat-3 Combination Pack, Femizol M)
Classes: Antifungals, Vaginal
- Dosing and uses of Monistat-1 Combination Pack, Monistat-3 Combination Pack (miconazole vaginal)
- Monistat-1 Combination Pack, Monistat-3 Combination Pack (miconazole vaginal) adverse (side) effects
- Warnings
- Pregnancy
- Pharmacology of Monistat-1 Combination Pack, Monistat-3 Combination Pack (miconazole vaginal)
Dosing and uses of Monistat-1 Combination Pack, Monistat-3 Combination Pack (miconazole vaginal)
Adult dosage forms and strengths
vaginal cream
- 2%
- 4%
vaginal suppository
- 100mg
- 200mg
Vulvovaginal Candidiasis
Vaginal 2% cream qHS x7 day
100 mg vaginal suppository qHS x7 day
200 mg vaginal suppository qHS x3 day
Pediatric dosage forms and strengths
vaginal cream
- 2%
- 4%
vaginal suppository
- 100mg
- 200mg
Vulvovaginal Candidiasis
Infants and children: Not indicated
Adolescents
- As adults
- Vaginal 2% cream qHS x7 days
- 100 mg vaginal suppository qHS x7 days
- 200 mg vaginal suppository qHS x3 days
Monistat-1 Combination Pack, Monistat-3 Combination Pack (miconazole vaginal) adverse (side) effects
Frequency not defined
Allergic contact dermatitis
Burning
Irritation
Itching
Maceration
Warnings
Contraindications
Pregnancy: 1st trimester
Known hypersensitivity to drug
Cautions
Hypersensitivity to other azoles
IV form not commercially available
Pregnancy and lactation
Pregnancy category: C
Lactation: unknown
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Monistat-1 Combination Pack, Monistat-3 Combination Pack (miconazole vaginal)
Distribution: widely to body tissues; penetrates well into inflamed joints, vitreous humor of eye, & peritoneal cavity, but poorly into saliva & sputum; crosses blood-brain barrier but only to a small extent Protein Bound: 91-93% Half-life elimination: multiphasic: initial: 40 min; secondary: 126 min; terminal: 24 hr
Metabolism: hepatic P450 CYP3A4
Excretion
Feces: ~50%
Urine: <1% as unchanged drug)
Mechanism of action
Interferes with mitochondrial & peroxisomal enzymes
Alters cell membrane permeability
